Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium

Ross Camidge, Laurie Gaspar, Glennwood Goss, Karen Kelly, Suresh Ramalingam, Karen Reckamp, George Simon, Ming Tsao, Howard West, Roy Herbst, David Johnson, Paul Bunn, Ramaswamy Govindan

Research output: Contribution to journalArticlepeer-review


Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.

Original languageEnglish
Pages (from-to)930-935
Number of pages6
JournalJournal of Thoracic Oncology
Issue number7
StatePublished - Jul 2009


  • Genomics
  • Lung cancer
  • Molecularly targeted therapy


Dive into the research topics of 'Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium'. Together they form a unique fingerprint.

Cite this